Company intelligence / Profile preview
AngioDesign
Warminster, Wiltshire, United Kingdom
- Ownership
- Private
- Employees
- ~3
- Development stage
- Preclinical
01
Overview
AngioDesign has developed lisW-S (lisinopril-tryptophan), a novel C-domain ACE inhibitor with no preclinical signs of toxicity in GLP toxicology tests. The compound shows a 15% decrease in systolic blood pressure similar to lisinopril, with evidence for decreased levels of bradykinin. When combined with an NEP inhibitor, it demonstrates antihypertensive and cardioprotective properties without affecting endothelial vasodilation[7].
- Therapeutic areas
- OtherCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Cape TownUniversity of BathUniversity of GlasgowAttoquant DiagnosticsSyngeneCedars-Sinai Medical Center[7]
Beyond the preview
Go deeper on AngioDesign.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AngioDesign.